In an article in Health Affairs, Rick van der Vegte and I argue that in four specific cases, the answer is yes.
…the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) developed a “value flower,” which aims to more comprehensively capture all elements of value relevant for measuring the value of a new health technology. Yet, the COVID-19 pandemic and subsequent roll-out of new treatments and vaccines has highlighted another value element that may need to be added to value discussion: the supply chain.
Overall, there are four high-priority areas where a health technology’s real-world benefits and risk are likely to be impacted by supply chain: (i) vaccines for contagious diseases, (ii) cell and gene therapies, (iii) digital medicines and therapeutics, and (iv) high-risk medications. Below, we review each of these cases in turn and argue that in these four cases, treatment value may be highly impacted by supply chain considerations.
Do read the whole article here.